Evidence map›Paper›PMID 40256022›Full record

ArticleInternational journal of ophthalmology2025

IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27.

Zong-Bo Wu, Gong-Yue Wang, Bei Wang, Xi Peng, Jia-Song Wang, Ming-Chang Zhang, Wen Geng, Hua-Tao Xie

Abstract read
In one paragraph

Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zong-Bo WuDepartment of Ophthalmology, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan 431800, Hubei Province, China.
Gong-Yue WangDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Bei WangDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Xi PengDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Jia-Song WangDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Ming-Chang ZhangDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Wen GengDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Hua-Tao XieDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the pathological features of ocular surface squamous neoplasia (OSSN) and evaluate the synergistic therapeutic effects of interferon-α2b (IFNα2b) and 5-fluorouracil (5-FU) on cellular proliferation, migration, apoptosis, and cell cycle of human oral squamous carcinoma cell line Cal27.

methodsTissue specimens from OSSN were processed with hematoxylin-eosin (HE) and immunofluorescence (IF) staining to characterize pathological changes. We analyzed the expression levels of four pivotal proteins involved in 5-FU metabolism: interferon alpha receptor (IFNAR), thymidylate synthase (TS), thymidine phosphorylase (TP), and dihydropyrimidine dehydrogenase (DPD). Cal27 cell lines were treated with a spectrum of concentrations of IFNα2b and 5-FU, either in isolation or in combination. Then, cell activity was measured utilizing CCK-8 assay and dose-effect curves were calculated, while tumor cell migration was detected by cell scratch experiments. Cal27 cells were added with IFNα2b and 5-FU in a non-constant ratio drug combination design and the corresponding combination index (CI) and fraction affected (Fa) were calculated with CompuSyn software. Western blot assay was conducted to quantify the expression of TP, TS, and DPD. Cell cycle and apoptosis were measured with flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick and labeling (TUNEL) assay.

resultsTreatment with both IFNα2b and 5-FU inhibited cell proliferation. Except for the lowest and highest doses of 5-FU, CI values for all other groups were below 1, suggesting a synergistic interaction. Low concentrations of IFNα2b and 5-FU both diminished the relative mobility of Cal27 cells, instead, a stronger inhibitory effect was observed when the two drugs were co-applied. The expression levels of TP and DPD in Cal27 cells were dose-dependently increased at a low concentration of IFNα2b. Low-dose IFNα2b combined with 5-FU significantly inhibited cell proliferation in G0/G1 phase compared to 5-FU monotherapy. Medium and high doses of IFNα2b and all concentrations of 5-FU could induce apoptosis in a concentration-dependent manner. The susceptibility to 5-FU treatment and apoptosis rates of tumor cells were elevated with low doses of IFNα2b.

conclusionBoth IFNα2b and 5-FU, when administered individually or in combination, effectively suppress the proliferation and migration of Cal27 tumor cells, induce cell apoptosis and arrest cell cycle. Low doses of IFNα2b increase the antitumor effects of 5-FU on Cal27 potentially through up-regulating the expression of TP, demonstrating a synergistic effect between IFNα2b and 5-FU.

Indexed as

5-fluorouracilcombination indexinterferon-α2bocular surface squamous neoplasiasquamous carcinoma cells

Identifiers

PMID40256022
PMCPMC11947539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.